

Jobst F Roehmel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3130828/publications.pdf>

Version: 2024-02-01

21
papers

2,252
citations

840119

11
h-index

752256

20
g-index

21
all docs

21
docs citations

21
times ranked

5640
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. <i>Cell</i> , 2022, 185, 493-512.e25.	13.5	122
2	Comparison of the Lung Clearance Index in Preschool Children With Primary Ciliary Dyskinesia and Cystic Fibrosis. <i>Chest</i> , 2022, 162, 534-542.	0.4	11
3	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two <i>ΔF508</i> Alleles. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 311-320.	2.5	49
4	The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN. <i>ERJ Open Research</i> , 2022, 8, 00139-2022.	1.1	9
5	Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+ T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 753-756.	1.5	7
6	The BEAT-PCD (Better Experimental Approaches to Treat Primary Ciliary Dyskinesia) Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2021, 57, 2004601.	3.1	16
7	Cross-reactive CD4 ⁺ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. <i>Science</i> , 2021, 374, eabh1823.	6.0	221
8	Untimely TGFβ ² responses in COVID-19 limit antiviral functions of NK cells. <i>Nature</i> , 2021, 600, 295-301.	13.7	146
9	Study protocol: the ear-nose-throat (ENT) prospective international cohort of patients with primary ciliary dyskinesia (EPIC-PCD). <i>BMJ Open</i> , 2021, 11, e051433.	0.8	18
10	Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases. <i>ERJ Open Research</i> , 2020, 6, 00408-2020.	1.1	18
11	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19). <i>Infection</i> , 2020, 48, 619-626.	2.3	79
12	SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. <i>Nature</i> , 2020, 587, 270-274.	13.7	1,115
13	Clinical manifestations and risk factors of arthropathy in cystic fibrosis. <i>Respiratory Medicine</i> , 2019, 147, 66-71.	1.3	11
14	Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against <i>Candida albicans</i> . <i>Cell</i> , 2019, 176, 1340-1355.e15.	13.5	321
15	Risk of piperacillin-induced hemolytic anemia in patients with cystic fibrosis and antipseudomonal treatment: a prospective observational study. <i>Transfusion</i> , 2019, 59, 3746-3754.	0.8	9
16	<i>Aspergillus</i> Bronchitis in Patients with Cystic Fibrosis. <i>Mycopathologia</i> , 2018, 183, 61-69.	1.3	65
17	Allergic bronchopulmonary aspergillosis is associated with pet ownership in cystic fibrosis. <i>Pediatric Allergy and Immunology</i> , 2016, 27, 597-603.	1.1	15
18	Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216937.	0.2	8

#	ARTICLE	IF	CITATIONS
19	Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis. PLoS ONE, 2016, 11, e0158193.	1.1	2
20	Arxula adenivorans causing invasive pulmonary mycosis and fungaemia in cystic fibrosis. Lancet, The, 2015, 385, 1476.	6.3	10
21	Hypersensitivity to parenteral antibiotics in patients with cystic fibrosis. Clinical and Translational Allergy, 2014, 4, P66.	1.4	0